HSS and Rothman Institute/Jefferson University Hospital to Participate in Clinical Trial for Elute's Antibiotic Loaded Bone Void Filler

ELUTE-IDE-HSS-Rothman

SALT LAKE CITY, Nov. 30, 2021 /PRNewswire/ -- Following Elute, Inc.'s Investigational Device Exemption (IDE) authorization from the US Food and Drug Administration (FDA) to use its EP Granules with Tobramycin™ in a pivotal clinical trial, the Hospital for Special Surgery (HSS), and the Rothman Orthopaedic Institute (Rothman) have agreed to become clinical sites to evaluate the safety and efficacy of the EP Granules. This addition of HSS and Rothman as clinical partners demonstrates the interest in exploring additional treatment options for difficult to treat periprosthetic joint infections, and expands the number of sites, facilitating patient enrollment. HSS and Rothman will join a group of Elute's clinical partners focused on improving patient care and driving clinical value. [ABSTRACT FROM PUBLISHER]